All In Biotech

Drug Trial Radar · NCT07339722

A Study of LY4515100 in Healthy Participants

A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants and an Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of LY4515100 and of LY4515100 on the Pharmacokinetics of CYP and Transporter Substrates in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 209 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

209

Planned (sponsor's estimate)

Start

Jan 15, 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.

Conditions

  • Healthy

Interventions

  • LY4515100 via SADDrug

    given orally

  • LY4515100 via MADDrug

    given orally

  • LY4515100Drug

    given orally

  • ItraconazoleDrug

    given orally

  • CaffeineDrug

    given orally

  • DigoxinDrug

    given orally

  • IohexolDrug

    given IV

  • MetforminDrug

    given orally

  • RosuvastatinDrug

    given orally

  • PlaceboDrug

    given orally

  • MidazolamDrug

    given orally

  • MidazolamDrug

    given IV

  • LevonorgestrelDrug

    given orally

  • Ethinyl EstradiolDrug

    given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and BTime frame: Day 1 up to Day 30

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Dallas, Texas · Recruiting

  • Fortrea Clinical Research Unit

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.